p53 is activated genetically by a set of kinases that are components of the calcium calmodulin kinase superfamily, including CHK2, AMP kinase, and DAPK-1. In dissecting the mechanism of DAPK-1 control, a novel mutation (N1347S) was identified in the death domain of DAPK-1. The N1347S mutation prevented the death domain module binding stably to ERK in vitro and in vivo. Gel filtration demonstrated that the N1347S mutation disrupted the higher order oligomeric nature of the purified recombinant death domain miniprotein. Accordingly, the N1347S death domain module is defective in vivo in the formation of high molecular weight oligomeric intermediates after cross-linking with ethylene glycol bis(succinimidylsuccinate).
The tumor suppressor protein p53 is a stress-activated DNAbinding protein and transcription factor that can induce a set of gene products implicated in growth arrest, apoptosis, redox balance, and cellular repair pathways (1) . Because p53 is mutated or inactivated frequently in human cancers, much effort is centered on determining the mechanisms whereby mutations inactivate the p53 protein, determining which gene products mediate the tumor suppressor activity of the protein, and identifying the enzymes that activate the protein as a tumor suppressor.
It is important to determine whether the p53 "activating" or "inhibitory" enzymes are also themselves mutation targets that stimulate cancer development. One key paradigm developed for p53 is that its activity in unstressed cells is held in check by an ubiquitin-dependent degradation pathway that promotes the rapid turnover of the protein. A set of E3 2 ligases that can turnover p53 by promoting its ubiquitination include the ringfinger-containing proteins MDM2, COP-1, CHIP, and PirH2 (2) . A promoter polymorphism in the MDM2 gene enhances cancer incidence thus highlighting the importance of identifying genetic changes that may alter disease incidence (37) . A second paradigm centers around the concept that the stresses or microenvironmental changes that activate p53 and relieve the protein of this negative regulation are quite distinct and include agents such as hypoxia, acidification, glucose starvation, oncogene activation, genome instability, microtubule dysregulation, type I interferon, exposure to irradiation, and viral infection (3) . The enzymes that play a role in linking these distinct stresses to p53 activation are beginning to be defined and include distinct protein kinase types, including casein kinase 2 and ATM (4) . Recent studies have interestingly shown that members of the calcium calmodulin kinase superfamily, including CHK2, AMPK, and DAPK-1 share the common feature of being genetic components of signaling pathways that activate the tumor suppressor activity of p53 (5-7). These calcium calmodulin kinase superfamily members differ in that they are activated by distinct stresses and provide a common evolutionary link between cellular stresses and p53 activation. Further, ATM, CHK2, LKB-AMP kinase, and DAPK-1 activities can be attenuated by point mutation or by gene silencing in human cancers.
The mechanisms driving p53 activation by phosphorylation is being defined by biochemical and genetic studies. In response to ionizing radiation, p53 is activated by an ATM-CHK2 signaling pathway that senses DNA strand breaks and leads to direct phosphorylation of p53 in its transactivation domain, p53 acetylation, and gene induction (8 -12) . The LKB-AMPK tumor suppressor pathway responds to metabolic stresses by activating p53 and inducing phosphorylation at the ATM site at Ser-15 (5) , although the molecular mechanism whereby LKB-AMPK fully activates p53 is not defined (13) . Finally, the tumor suppressor protein DAPK-1 is a component of an oncogenic signaling pathway that mediates p53 activation (7) . The biochemical mechanism whereby DAPK-1 activates p53 is undefined, but biological studies have shown that DAPK-1 can induce myosin light chain phosphorylation (14) , autophagy (15, 16) , and/or antagonize FAK (17) . Thus, three distinct physiological stresses known to activate p53 are now linked to three signaling components of the calcium calmodulin kinase superfamily that have the common feature of being genetic components of tumor suppressor pathways ATM-CHK2, LKB-AMPK, and DAPK-1.
In an attempt to begin to define the mechanism underlying how the tumor suppressor protein DAPK-1 functions at a molecular level, we have cloned the DAPK-1 gene and have identified a previously unidentified germ line mutation in the death domain. The death domain of DAPK-1 was identified originally in a genetic screen to be one of four functional domains required for DAPK-1 to exert its growth suppressive activity (18) . The death domain is thought to be a signaling module contained in pro-apoptotic proteins, including Fas, TNFR, FADD, and UNC5H2 (19 -21) . One recent report has indicated that the death domain of DAPK-1 forms a docking site required for its interaction with ERK (22) , identifying the first binding protein for the death domain of DAPK-1. Our analysis on the effects of the novel germ line mutation on death domain function indicates the mutation alters death domain oligomerization and attenuates ERK docking and associated apoptotic signaling. These data highlight a post-translational mechanism whereby the DAPK-1 tumor suppressor activity can be quenched in response to signal transduction events. Further, the relatively high penetrance of the death domain mutation in germ line DNA from at least one population set identifies a signaling pathway mutation that might affect DAPK-1 activity in apoptotic diseases of the immune system, ischemic injury, and cancer.
EXPERIMENTAL PROCEDURES
Sequencing from Genomic DNA Potential study participants from the Southampton population with previously diagnosed truncating mutations of BRCA1 were identified from the data base of the Wessex Clinical Genetics Service, Southampton. Genomic DNA was obtained for 116 BRCA1 mutation carriers, 20 male and 96 female. Age at time of screening for BRCA1 mutations ranged between 29 and 57 years. The clinical histories of all subjects were reviewed to ascertain age at first and subsequent malignancies. 59 gene carriers had developed breast cancer, and a further 14 had ovarian cancer. 10 patients had undergone prophylactic bilateral oophorectomy (5 after developing breast cancer), and 3 patients had undergone bilateral risk reducing mastectomy. All malignancies occurred in female subjects; male subjects were therefore excluded from all analyses of cancer incidence. 102 anonymous genomic DNA samples (46 male, 56 female, age range 16 -82), referred by the Wessex Clinical Genetics Service for genetic screening of non-neoplastic conditions, were obtained to provide an unmatched control group. Genotyping was performed using Pyrosequencing TM technology. Amplicons were generated in a 50-l reaction volume with 15 pmol each of DAPK-Forward (5Ј-gtg cct tct cgc cat ga-3Ј) and DAPKReverse (biotin-5Ј-ata ggc ctc ctg gcc att-3Ј), as well as Reverse DAPK-SNP (codon 1347) (biotin-5Ј-ttg gga gcc ccg tta-3Ј), 0.2 mM dNTPs, 1.5 mM MgCl 2 , 1ϫ Buffer II (500 mM potassium chloride and 100 mM Tris-HCl, pH 8.3) (Applied Biosystems), 1 unit of AmpliTaq Gold (Applied Biosystems) using 10 ng of genomic DNA. PCR conditions were 94°C for 7 min; 50 cycles with denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and elongation at 72°C for 30 s; 1 cycle at 72°C for 7 min; and a final hold at 15°C. Thermocycling was performed using a PTC-0225 DNA Engine Tetrad (MJ Research). Single-stranded biotinylated PCR products were prepared for Pyrosequencing using a Vacuum Prep Tool (Biotage AB). 3 l of Streptavidin Sepharose TM HP (Amersham Biosciences) was added to 37 l of binding buffer (10 mM Tris-HCl, pH 7.6, 2 M NaCl, 1 mM EDTA, 0.1% Tween 20) and mixed with 20 l of PCR product and 20 l of high purity water for 10 min at room temperature using a Variomag Monoshaker (Camlab). The beads containing the immobilized templates were captured onto the filter probes after applying the vacuum, and then washed with 70% ethanol for 5 s, denaturation solution (0.2 M NaOH) for 5 s, and washing buffer (10 mM Tris-acetate, pH 7.6) for 5 s. The vacuum was switched off, and the beads were released into a PSQ 96 well plate containing 45 l of annealing buffer (20 mM Tris-acetate, 2 mM MgAc 2 , pH 7.6), 0.3 M DAPK sequencing primer (5Ј-GTGCCTTCTCGCCATGA-3Ј). The samples were heated to 80°C for 2 min and then allowed to cool to room temperature. Pyrosequencing reactions were performed according to the manufacturer's instructions using the PSQ 96 SNP Reagent Kit (Biotage AB), which contained the enzyme and substrate mixture and nucleotides. Assays were performed using the nucleotide dispensation order AGTACGCGC. The sample genotype was determined using SNP Software (Biotage AB).
Plasmids and Site-directed Mutagenesis
The C terminus of DAPK-1 (amino acids 1313-1431) was cloned into the Gateway system vector pDONR221 (Invitrogen) using the following primers: Fwd 5Ј-GGGGACAAGTTTGTA-CAAAAAAGCAGGCTGGAAACTGAGTCGCCTGCTGG-ACCCG-3Ј and Rev 5Ј-GGGGACCACTTTGTACAAGAAAG-CTGGGTGTCACCGGGATACAACAGAGCTAAT-3Ј. This vector was used as a template to construct DAPK-1 polymorphic variants using the in vitro mutagenesis system QuikChange (Stratagene) as recommended by the manufacturer. HA-tagged ERK and MEK(EE) expression vectors were a gift of Steve Keyse (Dundee University, UK) HA-tagged DAPK-1 was a gift of Adi Kimchi (Weizmann Institute, Israel), and this allele (Asn-1347:Leu-1392) was mutated to derive the "founding" allele (Asn-1347:Phe-1392) and the "SNP" allele (Ser-1347:Phe-1392). The sequences of the primers used for mutagenesis are (bases which introduce amino acid change are underlined): amino acid 1347 SϾN (Fwd 5Ј-CAAAGTACAA-CACCAATAACGGGGCTCCCAAG-3Ј and Rev 5Ј-CTTGG-GAGCCCCGTTATTGGTGTTGTACTTTG-3Ј) and amino  acid 1392 FϾL (Fwd 5Ј-GGATGCCGCAGACCTTTTGCTG-AAGGCATCC-3Ј and Rev 5Ј-GGA TGC CTT CAG CAA AAG  GTC TGC GGC ATCC-3Ј) . For expression of glutathione S-transferase or His-tagged fusion protein in Escherichia coli, pDONR221-DAPK-1 vectors were recombined with the pDEST15/pDEST17 vector (Invitrogen) as recommended by the manufacturer. HA-tagged ERK was described previously, and p55-TNFR expression construct was obtained from David Dornan (Genentech). For expression in mammalian cells, the pDONR-DAPK-1 vectors were used as a template for PCR cloning into the p3XFLAG-myc-CMV-26 expression vector (Sigma), which has an N-terminal 3ϫFLAG tag and a C-terminal myc tag. The primers were designed to include EcoR1 and BglII restriction sites, and PCR products were cloned into the FLAG-myc vector at the same sites. The primers used were: Fwd 5Ј-TTGAATTCAAAACTGAGTCGCCTGCTGGAC-CCG-3Ј and Rev 5Ј-TTAGATCTATCCGGGATACAA-CAGAGCTAATGGA-3Ј.
Immunoblotting
HCT116 wt cells were grown in McCoy's medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen) at 37°C in a 5% CO 2 /H 2 O-saturated atmosphere. HEK293 cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen). Cells for transient transfection were plated out 24 h before transfection at ϳ1.5 ϫ 10 6 cells per 100-mm dish or 5 ϫ 10 5 cells per 60-mm dish. For Lipofectamine 2000 transfection (Invitrogen), 2 l of Lipofectamine was used for every 1 g of DNA transfected. Cells were harvested after a further incubation of 24 -36 h. Cells were lysed in ice-cold extraction buffer (50 mM Tris (pH 7.4), 150 mM NaCl 2 , 5 mM EDTA, 0.5% Nonidet P-40, 5 mM NaF, 1 mM sodium vanadate, 1ϫ protease inhibitor mixture) for 30 min and centrifuged at 13,000 rpm for 15 min to remove insoluble material. The protein content of cell extracts was measured using Bio-Rad reagent (Bio-Rad). Typically, 50 g of cell extract was immunoblotted. Samples were resolved by denaturing gel electrophoresis, typically 4 -12% precast gels (Novex) and electrotransferred to Hybond C-extra nitrocellulose membrane (Amersham Biosciences), blocked in PBS-10% nonfat milk for 30 min, then incubated with primary antibody overnight at 4°C in PBS-5% nonfat milk-0.1% Tween-20. After washing (3 ϫ 10 min) in PBS-Tween 20, the blot was incubated with secondary antibody, either horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibody (Dako, 1:5000), for 1 h at room temperature in PBS-5% nonfat milk-0.1% Tween 20. After washing (3 ϫ 10 min) in PBS-Tween 20, proteins were visualized by incubation with ECL reagent (Sigma). Equal protein loading was confirmed with Ponceau S staining. FLAG antibody (M2) and FLAG M2-conjugated agarose were purchased from Sigma. Myc antibody (9E10) was purchased from Cancer Research UK. HA and PARP antibodies were purchased from Cell Signaling. The anti-HA antibody is from Upstate (07-221), the anti-ERK antibody (9102), anti-phospho-ERK (9101), and anti-PARP antibody (9542) are from Cell Signaling.
Cell Culture: Cross-linking of Proteins, and Immunoprecipitation 16 h post-transfection, HCT116wt cells expressing FLAGmyc-tagged DAPK-1 proteins were cross-linked with 2 mM EGS (Pierce) for 1 h at 37°C in a 5% CO 2 /H 2 O-saturated atmosphere. Cross-linking was terminated by washing cells in PBS and harvesting. For immunoprecipitation of cross-linked proteins, 30 l of FLAG M2 beads (Sigma) were incubated overnight at 4°C with rotation, together with 500 l of cell extract (ϳ1 mg) prepared in extraction buffer (50 mM Tris (pH 7.4), 150 mM NaCl 2 , 5 mM EDTA, 0.5% Nonidet P-40, 5 mM NaF, 1 mM sodium vanadate, 1ϫ protease inhibitor mixture). The bead pellets were then washed five times in lysis buffer before resuspension in 100 l of FLAG peptide elution buffer (0.25 g/l FLAG peptide (Sigma) resuspended in TBS (50 mM Tris, pH 7.5, 150 mM NaCl) and mixed with constant rotation for 2 h. Eluted proteins were then resuspended in 3ϫ SDS-loading buffer and analyzed by denaturing gel electrophoresis and immunoblotting with antibodies specific to the myc tag. For immunoprecipitation of exogenous HA-ERK from HCT116 wt cells, HA antibody (Cell Signaling) was incubated with 30 l of washed Protein G beads (Sigma) overnight at 4°C with constant rotation, together with cell extract (ϳ1 g) diluted to a volume of 500 l in extraction buffer (50 mM Tris (pH 7.4), 150 mM NaCl 2 , 5 mM EDTA, 0.5% Nonidet P-40, 5 mM NaF, 1 mM sodium vanadate, 1ϫ protease inhibitor mixture). The bead pellets were then washed five times in extraction buffer before being resuspended in 3ϫ SDS-loading buffer and analyzed by denaturing gel electrophoresis and immunoblotting. To monitor PARP cleavage, HEK293 cells or HCT116 wt cells were seeded and transfected 24 h later with vectors encoding the respective death domain modules (5 g, Asn-1347:Phe-1392 or Ser-1347: Phe-1392), empty vector control, together with p55-TNFR (0.5 g), or DAPK-1, ERK, and MEK(EE) vectors (1 g of each). 16 h post-transfection cells were harvested and immunoblotted for PARP cleavage of FLAG-tagged death domain expression.
Apoptosis Assays
TUNEL Assay-HCT116wt or HEK293 cells were seeded directly onto cover slips in 6-well plates. 18 h later cells were transfected with the indicated amounts of expression vectors for a further 24 h. Following transfection cells were fixed in 1% paraformaldehyde for 10 min at room temperature. Apoptotic cells were labeled using Apoptag Plus Fluorescein In Situ Apoptosis Detection Kit S7111 (Chemicon) according to the manufacturer's instruction and viewed by fluorescence microscopy.
Annexin V staining-HCT116wt cells were seeded into 6-well plates. 18 h later cells were transfected with the indicated amounts of expression vectors for a further 24 h. To include any floating cells, media was collected into fluorescence-activated cell sorting tubes and centrifuged at 1700 rpm for 4 min to leave a cell pellet. Media was then discarded from tubes. Petri dishes were washed with 2 ml of PBS, PBS was discarded, and then 1.5 ml of trypsin was added to each plate and the mixture was incubated until cells became detached. Following cell detach-ment 1.5 ml of McCoy's 5A medium supplemented with 10% fetal calf serum was added to each plate to stop the trypsin. The cell suspensions were then added to each of the relevant cell pellets from the floating cells. Samples were centrifuged at 1700 rpm for 4 min, pellets were resuspended in 1 ml of McCoy's 5A medium supplemented with 10% fetal calf serum, and the mixture was incubated for 5 min. Samples were centrifuged for a further 4 min at 1700 rpm prior to resuspension in 1 ml of ice-cold PBS. Samples were centrifuged for a further 4 min at 1700 rpm. Apoptotic cells were detected using TACS Annexin V-FITC Apoptosis Detection Kit (R&D Systems) according to the manufacturer's instruction and analyzed by flow cytometry.
PARP Cleavage-HEK293 cells were seeded into 6-cm plates. 18 h later cells were transfected with the indicated amounts of expression vectors (DAPK-1, ERK, and MEK (EE)) for a further 24 h. Cells were lysed in ice-cold TNN buffer (150 mM NaCl, 50 mM Tris, pH 8, 0.1% Nonidet P-40, phosphatase inhibitor mixture, 5 mM NaF, and 1 mM sodium orthovanadate) for 30 min on ice prior to centrifugation at 13,000 rpm for 15 min at 4°C. Cleared lysates were then resolved by SDS-gel electrophoresis, and proteins were detected using Rabbit polyclonal antibody to PARP (Cell Signaling #9542).
Gel Filtration
To examine effects of the death domain mutation on its oligomerization in vitro, a Superdex 200 10/300 GL (Tricon) high performance gel filtration column was equilibrated with buffer (PBS, 5% glycerol, 1 mM benzamidine pre-filtrated with a Millipore filter 0.22 m). Sample containing the purified recombinant death domain protein (800 g) was injected and eluted into fractions of 1 ml each. The amount of protein eluted into each fraction was then quantified using Bradford assay. The equipment employed in the gel filtration was AKTA fast protein liquid chromatography (Amersham Biosciences) and fraction collector FRAC-950 (Amersham Biosciences). The software used was UNICORN version 4.10 (Amersham Biosciences). Molecular weight markers were obtained from Sigma.
Enzyme-linked Immunosorbent Assay for Measuring ERK: Death Domain Stability
A 96-well microtiter plate (Corning Inc.) was coated with purified DAPK death domain protein diluted in 0.1 M Na 2 HCO 3 , pH 8.0, and incubated overnight at 4°C. Each well was washed 6ϫ with PBS containing 0.1% Tween 20 (PBS-T) followed by incubation for 1 h at room temperature with gentle agitation in PBS-T supplemented with 3% bovine serum albumin. The wells were washed 6ϫ with PBS-T prior to incubation with appropriate amounts of purified ERK protein (Upstate) diluted in PBS-T 3% bovine serum albumin for 1 h at room temperature. After 1 h incubation the plate was washed again 6ϫ with PBS-T and incubated with antibody specific to ERK (p44/42 MAPK antibody #9102, Cell Signaling) for 1 h at room temperature. Following a further 6ϫ washes with PBS-T wells were incubated with secondary rabbit horseradish peroxidase antibodies followed by further washing and ECL. The results were quantified using Fluoroskan Ascent FL equipment (Labsystems) and analyzed with Ascent Software version 2.4.1 (Labsystems).
RESULTS

Asn 3 Ser Mutations at Codon 1347 in the Death Domain
Attenuate ERK Binding-Upon cloning and sequencing of the DAPK-1 gene cloned from total RNA of a tumor cell line, we identified two mutations in the death domain that differed from the original wild-type sequence (Fig. 1 ). These two mutations include an Asn 3 Ser mutation at codon 1347 and an Leu 3 Phe mutation at codon 1392. To determine whether the Asn 3 Ser mutation at codon 1347 or the Leu 3 Phe mutation at codon 1392 alters the function of the death domain, biochemical characterization was initiated. The only direct biochemical function defined for the death domain of DAPK-1 is that it functions as an ERK docking site leading to phosphorylation at amino acid 735 (22) . Mutation of the ERK docking site on DAPK-1 from 1392-LXL-1394 to 1392-AXA-1394 attenuates ERK binding (22) . This latter characterization utilized the Leu-1392 allele of DAPK-1 that differs from the gene we have cloned harboring the Phe-1392 codon. It is possible that the L to F mutation at codon 1392 alters ERK binding either positively or negatively, and we first determined whether the L to F mutation altered ERK binding. The transfection of the minimal death domain alleles, Asn-1347:Leu-1392 or Asn-1347:Phe-1392, did not alter the ability of the death domain to co-immunoprecipitate with transfected HA-tagged ERK (Fig. 2A, lanes 2 and 3   FIGURE 1 . Location of SNP mutations in the death domain of DAPK-1. The functional domains of DAPK-1 are as indicated; kinase domain, an inhibitory autophosphorylation site, calmodulin domain, ankyrin repeats, an ERK phosphorylation site and docking site (22) , and the death domain. The mutations described in this report within the death domain at codons 1347 and 1392 that differ from the originally cloned wild-type allele are highlighted as indicated: N Ͼ S and L Ͼ F. versus 1). These data suggest that the original identification of ERK as a death domain binding protein at the LXL motif is not altered by the Phe-1392 substitution.
We subsequently evaluated whether the Asn 3 Ser mutation at codon 1347 alters ERK binding despite the fact that this mutation lies out with the LXL-containing ERK docking site. The transfection of the isolated death domain containing the four permutations at codons 1347 and 1392 did not alter the steady-state levels of the death domain (Fig. 2B,  lanes 2-5 versus 1) . However, the co-transfection of ERK with the isolated death domain variants differentially alters ERK binding after co-immunoprecipitation (Fig. 2C,  lanes 2-5 versus 1) . The Ser-1347 mutation on either the Leu-1392 or Phe-1392 background attenuated ERK binding (Fig. 2C , lanes 3 and 5 versus 2 and 4) identifying this Asn to Ser mutation as having a specific functional defect.
The studies above utilized death domain transfected into human cells, and it was important to determine whether the mutation directly attenuates ERK binding to the death domain in vitro. As such, the N1347S death domain miniprotein variants were purified from recombinant E. coli expression strains (Fig. 2D) , and binding activity to ERK was measured in a quantitative enzyme-linked immunosorbent assay. The addition of increasing amounts of ERK resulted in a dosedependent increase in complex formation to the Asn-1347 death domain module, whereas ERK binding was attenuated when using the death domain encoded by the Ser-1347 allele (Fig. 2E) . These data indicate that the death domain N1347S mutation directly alters the ERK binding interface.
The Asn 3 Ser Mutation at Codon 1347 Disrupts Death Domain Oligomerization-It was surprising that the mutation at codon 1347 disrupted ERK binding despite the fact that this lies outside the LXL ERK binding site at codon 1392 (22) . These data suggest that alter- ations in death domain conformation might alter ERK binding by as yet undefined determinants. The death domain modules Fas and TNFR are capable of forming oligomers in solution and gave rise to the suggestion that they may form oligomeric scaffolds in vivo (24) . However, this is not always the case, because the death domain of the neurotrophin receptor remains monomeric in solution (25) . We investigated therefore whether or not the DAPK-1 death domain can form oligomers and whether the Asn 3 Ser codon 1347 mutation alters this property.
When the codon 1347 amino acid sequences in the death domain of DAPK-1 are highlighted with respect to the putative oligomeric structure, then it is striking that the localization is confined to a putative interdomain interface between two monomeric subunits (Fig. 3, A and B) . Further, an inactivating mutation in the death domain of murine Fas (lpr) resides at the N-terminal position of helix 3, which is distal to the position of the codon 1347 DAPK-1 death domain mutation at the C-terminal position in helix 3 (Fig. 3F) . It therefore remained possible that defects in ERK binding due to the codon 1347 mutation might relate to alterations in the oligomeric structure of the death domain due to helix 3 distortions. As such, the death domain encoded by the Asn-1347:Phe-1392 allele was first transfected into cells without co-transfected ERK to determine whether the module is, in fact, able to form oligomers. Potential oligomers were fixed in vivo by the use of the membrane permeable bi-functional cross-linking reagent EGS. After 24 h, transfected cells were incubated with EGS for various times and increasing concentrations (data not shown) and lysates immunoblotted to evaluate oligomerization status of the death domain. Under limiting cross-linking conditions, the majority of the death domain remains monomeric (Fig. 3C, lane 2) . In contrast cells incubated with EGS exhibit significant cross-linking of the death domain as defined by higher molecular weight bands (Fig. 3C, lane 3 versus lane 2) . These data are consistent with the possibility that death domain of DAPK-1 can form oligomers (Fig. 3B) .
The respective death domain modules were subsequently transfected into cells to determine whether the Asn 3 Ser mutation confers changes in oligomerization. The Asn 3 Ser mutation might enhance oligomerization and preclude ERK docking, or it might block quaternary or tertiary structure and reduce the extent of oligomerization that might be important for ERK interactions. After 24 h, cells were incubated with EGS under conditions where the majority of the death domain encoded by the Asn-1347 allele was assembled into higher order oligomers and immunoblotted to evaluate oligomerization status of the Asn 3 Ser mutant protein. Death domain modules containing the Leu or Phe mutation in the Asn-1347 background displayed similar assembly into oligomeric intermediates and loss of the monomeric species (Fig. 3D, lanes 2  and 4) . By contrast, the protein modules containing the Ser-1347 mutation in either the Leu-1392 or Phe-1392 background exhibited attenuated assembly into the multi-protein complexes with significant monomeric isoforms remaining (Fig.  3D, lanes 3 and 5 versus 2 and 4) .
These data provide a mechanism to suggest how ERK binding might be attenuated by the Ser-1347 mutation as the death domain module becomes defective in its assembly into a multiprotein complex in cells. In fact, when the highly purified Asn-1347 death domain miniprotein was applied to gel filtration, the protein formed relatively high molecular weight oligomers (Ͼ600-kDa relative molecular mass) with an apparent equilibrium between a lower molecular mass oligomer with an apparent molecular mass of ϳ150 kDa (Fig. 3E, left panel) . By contrast, the death domain miniprotein encoded by the Ser-1347 allele produced a population of molecules with a shift in the equilibrium between the large and smaller oligomers and the majority eluted later on the gel filtration column (Fig. 3E, right  panel) . The correlation between higher oligomeric structure of the death domain (Fig. 3E ) and ERK binding (Fig. 2E) suggests that the ERK docking interface in the death domain is not just defined by a simple linear epitope.
Asn 3 Ser Mutation Attenuates the Biological Activity of Full-length DAPK-1-The studies above evaluated the effects of the DAPK-1 mutation on the isolated activity of the death domain but do not address the effects of the mutation on fulllength DAPK-1 function. Expression vectors encoding fulllength HA-tagged DAPK-1 (Asn-1347:Phe-1392 allele and Ser-1347:Phe-1392) were developed and used to evaluate DAPK-1 function in ERK binding and in oligomerization. The transfection of either gene into cells resulted in similar steady-state levels of DAPK-1 produced (Fig. 4A, lanes 2 and 3 versus 1) . Further, the co-transfection of ERK into cells (Fig. 4B, lanes  4 -6) did not alter steady-state levels of DAPK-1 protein (Fig.  4A, lanes 5 and 6) . The immunoprecipitation of DAPK-1 protein (Asn-1347:Phe-1392) using an anti-DAPK-1 antibody (Fig.  4C, lanes 2 and 5) resulted in significant co-precipitation of ERK (Fig. 4D, lanes 5 versus 4) . However, the immunoprecipitation of DAPK-1 encoded the Ser-1347:Phe-1392 allele using UNC5H2 (B) . C, the Asn-1347 death domain forms oligomers in vivo. Cells were transfected with expression vectors encoding the FLAG-tagged death domain and subject to in vivo cross-linking with EGS or Me 2 SO control for 1 h to limit the extent of potential cross-linking of the death domain. Cells were harvested, lysed, and immunoblotted with anti-FLAG IgG to define changes in the assembly of the death domain into intermediate structures. D, the S1347death domain exhibits defects in oligomerization in cells. Cells were transfected with expression vectors encoding the FLAG-tagged Asn-1347 variants (lanes 2 and 4) or Ser-1347 death domain variants (lanes 3 and 5) as indicated and subject to in vivo cross-linking with EGS or Me 2 SO control under conditions where the majority of the death domain encoded by the Asn-1347 allele has been assembled into oligomers (lanes 2 and 4) . Cells were harvested and immunoprecipitated/immunoblotted as indicated under "Experimental Procedures" to define changes in the assembly of the death domain into intermediate structures. E, the Ser-1347 death domain exhibits defects in oligomerization in vitro. The purified death domain miniproteins (as in Fig. 2D ) were injected onto a gel filtration column as indicated under "Experimental Procedures." Elution of the death domain proteins (Asn-1347 death domain module is in the left panel, and the Ser-1347 mutant death domain elution is depicted in the right panel) was measured as a function of elution volume (in milliliters, as indicated) and integrated to molecular weight markers, as indicated by the arrows. F, the location of the DAPK-1 mutation in helix-3 of the death domain in relation to the Fas mutation lrp, which is known to denature the Fas module (27) . The sequence of the helix 3 region from mouse Fas, TNFR, and human DAPK-1 are indicated. The amino acids in red highlight the position of the mutation in Fas and TNFR, respectively (V238N and L1337N) . The green amino acid in DAPK-1 (N1347S) highlights the position of the mutation relative to helix 3 (underlined).
an anti-DAPK-1 antibody (Fig. 4C, lanes 3 and 6) did not result in significant co-precipitation of ERK (Fig. 4D, lane 6 versus  lanes 4 and 5) . These data are consistent with the inability of the minimal death domain (encoded by the Ser-1347 allele) to bind to ERK in a co-precipitation assay and indicates that the single point mutation in full-length DAPK-1 is sufficient to prevent it assembling into an ERK multi-protein complex in vivo.
Although the N1347S mutation in the minimal death domain revealed differences in oligomerization in vivo (Fig. 3) , whether this mutation confers changes in full-length DAPK-1 assembly in vivo requires examination. The DAPK-1 expression vector (Asn-1347:Phe-1392 allele) was first transfected into cells to determine whether the module is able, in fact, to form oligomers. Potential oligomers were fixed in vivo, as above (Fig. 3) by the use of the membrane permeable cross-linking reagent EGS. After 24 h, transfected cells were incubated with EGS, and lysates were immunoblotted to evaluate the oligomerization state of full-length DAPK-1. Under these limiting cross-linking conditions, where the majority of DAPK-1 remained uncrosslinked, a significant pool of full-length DAPK-1 (Asn-1347:Phe-1392 allele) was cross-linked to a single high molecular weight species as well as exhibiting a "smear" into higher molecular weight cross-linked adducts (Fig. 4E, lane 5 versus 2 ). By contrast, the full-length DAPK-1 vector encoding the Ser-1347: Phe-1392 allele did not exhibit any detectable cross-linking in vivo (Fig. 4E, lane 6 versus 5) . The immunoprecipitation of the cross-linked DAPK-1 adducts resulted in significant proteolysis of the DAPK-1 oligomers (Fig. 4F) , thus it was difficult to identify selected proteins in complex with the cross-linked fulllength DAPK-1 protein. Nevertheless, these data highlight the effect the Ser-1347 mutation has on full-length DAPK-1 multiprotein complex assembly in cells. Presumably this defect will be manifest in DAPK-1 signaling assays, and a range of DAPK-1 assays were developed to determine which intracellular pathways are affected by the N1347S mutation.
In defining the function for the death domain, it was originally suggested that the mini-module is required for DAPK-1 to induce cell death, because small peptides from this region act as dominant negative effectors of DAPK-1 apoptotic function (18) , and the death domain can attenuate TNF-mediated apoptosis (19) . Further, the lpr mutation in the murine death domain of Fas denatures the module and reduces intracellular signaling induced by the TNF pathway (26, 27) . We examined whether the mutation at codon 1347 attenuates the biological function of the death domain. A previous report has shown that the death domain of DAPK-1 (a Asn-1347:Leu-1392 allele) can attenuate p55-TNFR-dependent cell death (19) . We evaluated whether the Asn 3 Ser codon 1347 mutation in the death 1-3) . Cells were harvested and immunoprecipitated followed by immunoblotting as indicated under "Experimental Procedures" to define changes in the assembly of the full-length DAPK-1 into intermediate structures. domain affected the ability of the mini-module to act as a dominant-negative effector and block TNF-dependent signaling. Transfection into HEK293 cells of p55-TNFR induced significant PARP cleavage (Fig. 5A, lane 3 versus 2) , which is a classic molecular indicator of apoptosis being triggered. The Asn-1347 death domain module was able to attenuate PARP cleavage (Fig. 5A, lane 4 versus 3) , which is consistent with previous reports showing that the death domain can attenuate p55-induced apoptosis (19) . By contrast, the Ser-1347 miniprotein was unable to attenuate p55-TNFR signaling (Fig. 5A, lane 5  versus 3 ) suggesting that the mutation produces an unstable module that cannot act as a dominant negative effector of the DAPK-1-dependent TNFR signaling pathway. Transfected amounts of the death domain modules are depicted in Fig. 5B .
Full-length DAPK-1 expression vectors encoding the Asn or Ser amino acid at codon 1347 were also tested in TNFR-mediated pro-apoptotic assays. Transfection of the TNFR-1 alone gave rise to significant increases in PARP cleavage (Fig. 5C,  lanes 2 versus 1) . The co-transfection of full-length DAPK-1 (N1347) induced marginal increases in the levels of PARP cleavage (Fig.  5C, lanes 3 versus 2) , whereas the full-length DAPK-1 encoded by the Ser-1347 allele reduced basal TNFR-1-mediated PARP cleavage (Fig. 5C, lane 4 versus 2) . Transfected amounts of full-length DAPK-1 proteins are depicted in Fig. 5D . These data together indicate that the 1347 codon substitution can alter the pro-apoptotic activity of DAPK-1. However, the death domain module is not known to recruit ERK in the TNFR-mediated signaling pathway, and the key biochemical defect we have identified in the Ser-1347 allele was inactivity in ERK binding. As such, we investigated whether the Ser-1347 mutation altered the pro-apoptotic activity of DAPK-1 in an ERK-dependent apoptotic cell system.
The Asn 3 Ser Mutation in DAPK-1 Inhibits ERK-mediated Apoptosis-To evaluate whether the death domain mutation alters ERKmediated apoptosis, we first had to set up a cell-based system that can measure MEK-dependent activation of ERK, as defined by elevated ERK phosphorylation. The transfection of activated MEK (MEK EE) into cells induced elevated phosphorylation of endogenous ERK (Fig. 6A, lane 2 versus 3) , relative to total ERK protein (Fig. 6B) . Further, the co-transfection of activated MEK with ERK elevated phosphorylation of the transfected ERK protein (Fig. 6A, lanes 4 versus 1) . Having defined an assay where ERK can be activated by MEK, a series of assays were developed that addressed whether the ERK:DAPK-1 pro-apoptotic pathway is altered by the N1347S mutation in DAPK-1. The first assay evaluated changes in Annexin V staining, which is an indicator of early events in apoptosis. The transfection of DAPK-1, MEK-ERK, or MEK-ERK-DAPK-1 induced differential changes in Annexin staining (Fig. 6C) . The DAPK-1 Asn-1347 allele induced more Annexin V staining than the DAPK-1 Ser-1347 allele (Fig. 6C, lanes 2  versus 3) . Further, MEK-ERK co-transfection with the Asn-1347 allele of DAPK-1 allele induced the most significant changes in Annexin V staining, relative to the MEK-ERK cotransfection with the Ser-1347 allele of DAPK-1 (Fig. 6C, lanes 5  versus 6) . Consistent with this, immunoblotting for PARP cleavage as a distinct measure of apoptosis also revealed that the Asn-1347 DAPK-1 allele was more effective at inducing a pro-apoptotic pathway in cooperation with MEK-ERK, relative to the DAPK-1 Ser-1347 allele (Fig. 6D, lanes 5 versus 6) . The final assay used to determine whether the DAPK-1 death domain mutation at codon 1347 altered MEK-ERK-DAPK-1 pro-apoptotic signaling was TUNEL, which measures changes in chromatin structure and induced DNA breaks. Similar to that observed with Annexin V staining or PARP proteolysis, the co-transfection of MEK-ERK, and Asn-1347 allele of DAPK-1 induced the most pronounced DNA cleavage ( Fig. 7D; summarized in Fig.  7G ). By contrast, the DAPK-1 Ser-1347 allele was defective in the induction of DNA damage in cooperation with MEK and ERK ( Fig. 7F ; summarized in Fig. 7G ). Together, these data provide evidence that the death domain codon N1347S missense mutation can reduce death domain oligomerization, reduce ERK binding, and prevent activated ERK-mediated apoptosis.
N1347S Allele Is a Novel Germ Line Mutation in DAPK-1-Our
cloning from a tumor cell line, with a wild-type p53 pathway, of a mutant death domain allele at both codons 1347 and 1392 prompted the biochemical characterization summarized above to determine whether the mutations would have any functional consequences. Although the Leu 3 Phe 1392 codon mutation did not reveal any defects, significant biochemical differences were observed by the Asn 3 Ser codon 1347 mutation and as such, we set out to determine whether the codon 1347 mutation was tumor-derived or a germ line, because the sequence differs from the published sequence (Asn-1347: Leu-1392). The alleles might have been tumor-derived due to selection pressures in cancer cells, and if so we would need to examine mutation frequency in a range of cancers to define the penetrance. Alternatively, the mutations might be germ line mutations in patients, and we would therefore need to sequence normal genomic DNA to determine whether or not the mutations are rare or common. Preliminary data indicated that the Asn to Ser mutation at codon 1347 was not FIGURE 7 . ERK-mediated apoptosis as defined using a TUNEL assay is inhibited by the N1347S codon mutation in DAPK-1. A-F, the N1347S death domain mutation attenuates ERK-DAPK-1-dependent changes in TUNEL staining. HCT116 cells were transfected as indicated with vector only, ERK, full-length DAPK-1 (Asn-1347 and Ser-1347 alleles), MEK, a combination of the two, or all three together. Cells were fixed for TUNEL assay as indicated under "Experimental Procedures," and representative images are highlighted. G, quantitation of apoptosis frequency using TUNEL from A-F. The percentages of apoptotic cells were calculated relative to the total number of cells using Image J software (National Institutes of Health). H, summary of two distinct stages where ERK-DAPK-1 axis can contribute to cell survival or apoptosis. DAPK-1 can function as a survival factor (43) or a pro-apoptotic factor (22) . When ERK activation induces phosphorylation of p90RSK kinase, this attenuates DAPK-1-dependent apoptotic function and induces a survival pathway (40) . By contrast, if ERK activation triggers a direct docking-dependent interaction with the death domain of DAPK-1, then this triggers a pro-apoptotic pathway. The naturally occurring N1347S mutation allows a direct test and independent evidence supporting that the death domain is required for ERK-mediated apoptosis.
tumor-derived, because it was detected upon sequencing normal genomic DNA from selected patient sets (data not shown, see below). Interestingly, upon examination of the mutation frequency at codon 1392 using normal genomic DNA, we were surprised to find no evidence for the Leu-1392 allele, which was the original cDNA expressed from the DAPK-1 locus (23). In over 250 different genomic DNA samples analyzed, the amino acid encoded by codon 1392 was phenylalanine (Fig. 8A , data not shown). Upon examination of the death domain sequence in other species, the Asn-1349:Phe-1392 allele was the only sequence observed (Fig. 8D) , suggesting that this might be the founding member in the human population. Because the Leu-1392 mutation has not yet been observed in our analyses, it might have originally been a tumor cell line derived mutation or there may be other genetic backgrounds which have harbored a SNP change at this site.
To evaluate the frequency of codon 1347 mutation in the population, genomic DNA was first sequenced from distinct patient groups to acquire more statistically significant data on the relative frequency of the alleles in the general population. In the first group of patients genomic DNA from normal volunteers was sequenced to determine the relative frequency of the 1347 codon mutation. In the normal control group, patients homozygous for the amino acid asparagine at codon 1347 were represented at 37.8%, patients heterozygous for asparagine and serine at codon 1347 were observed at a frequency of 47.3%, and patients homozygous for serine at codon 1347 were observed at 14.9% (Fig. 8B) . In a second set of patients, we also evaluated the penetrance of the codon 1347 alleles in normal genomic DNA from cancer patients with a BRCA1 germ line mutation (Fig.  8C ). In this sample group, patients homozygous for the amino acid asparagine at codon 1347 were represented at 45.3%, patients heterozygous for asparagine and serine at codon 1347 were observed at a frequency of 41.9%, and patients homozygous for serine at codon 1347 were observed at 12.8% (Fig. 8C) . The bias against a higher frequency for the homozygous mutant Ser-1347 codon in both groups might suggest a selection pressure against the double mutant Ser-1347 allele; however, larger population analysis is required for this to be substantiated. If there were selections against the homozygous mutant alleles, then this might suggest a toxic role for this homozygous allele in DAPK-1 mediated development. Regardless, the data indicate that there can be a relatively high degree of the 1347 codon mutation in a patient group. Because the founding allele in humans is apparently Asn-1347:Phe-1392 (Fig. 8D) , we propose that the codon Asn-1347:Phe-1392 is the wild-type allele and the Ser-1347:Phe-1392 allele is SNP allele based on divergence from the conserved death domain sequence (Fig. 8D) . The SNP is also inactivating based on its inability to function biochemically in ERK-dependent pathways (Figs. 2, 4, 6, and 7) . However, whether the SNP alters DAPK-1 interaction in other signaling pathways remains to be determined.
DISCUSSION
Key genetically defined activators of p53 are members of the calcium calmodulin kinase superfamily and include ATM-CHK2, DAPK-1, and LKB-AMPK. Mutations exist in genes encoding ATM, CHK2, and LKB that can attenuate the p53 response, but DAPK-1 is not known to be mutated in human cancers. However, DAPK-1 is thought to function like a tumor suppressor in that its gene expression can be attenuated by promoter methylation (38) . DAPK-1 was originally identified in an antisense screen as a gene implicated in interferon-␥-induced apoptosis in HeLa cells (23) . DAPK-1 is now known to be involved in a TNF-mediated apoptotic pathway (19) , suppression of metastasis via integrin degradation (17, 39) , an oncogene-driven p53-dependent checkpoint pathway (7), and its apoptotic function is either inhibited by a RSK-dependent pathway or stimulated by an ERK-mediated pathway (22, 40) . The attenuation of the pro-apoptotic function of DAPK-1 by promoter methylation is one of the key mechanisms thought to reduce DAPK-1 tumor suppressor activity. However, in renal cancers, the DAPK-1 gene is hypermethylated, yet significant expression of the protein is retained suggesting post-translational mechanisms might exist for reducing the specific activity of the protein (28) , possibly by RSK (40) . We also surprisingly show relatively high level expression of DAPK-1 protein in breast cancers (data not shown) suggesting the protein expression can be readily achieved in vivo, despite the fact that the gene is generally held to be silenced in cancers. In this report, we identify a novel germ line mutation in DAPK-1 in a functionally significant region of the protein, the pro-apoptotic death domain, which might have implications for post-translational attenuation of the DAPK-1 tumor suppressor pathway in diseases with modified pro-apoptotic pathways.
Functional domains of the DAPK-1 protein have been isolated using a genetic screen searching for mini-domains of DAPK-1 that act in a dominant negative function over DAPK-1, and four modules were found, including the death domain (18) . The death domain serves as a docking site for ERK thus catalyzing DAPK-1 phosphorylation by ERK at Ser-735 (22) , and the death domain allows, in part, DAPK-1 assembly into an UNC5H2 multiprotein complex (20) . The structure of the death domain is predicted based on superimposition of the amino acids with homology to other members of the death domain, including the neurotrophin receptor, UNC5H2, Fas, and FADD (Fig. 3) . The generic death domain contains two sets of ␣-helices arranged with three helices packed parallel in one plane perpendicular to another packing of three helices. The Asn 3 Ser mutation at codon 1347 is predicted to occur at the edge of a putative linker between helix 3 and 4. In this report, we provide evidence that the DAPK-1 death domain is oligomeric in vitro and in vivo and that a germ line mutation can attenuate the extent of its oligomerization and ERK docking.
Apoptosis plays important physiological functions in programmed cell death during fetal development, maintaining tissue integrity for example as a tumor-suppressing mechanism or in ischemic injury-dependent repair, immune system development, and as a defense mechanism to combat infection by viruses and micro-organisms. Defects in the apoptotic responses are therefore responsible for disease development, including cancer progression, ischemic injury responses, and immune system dysfunction. There is growing realization that the apoptotic program is maintained by a proteome-like network where various nodes are linked by conserved protein domain modules that serve as signatures for allowing cross-talk between the various interacting signals. Some examples of the conserved pro-apoptotic domains include: death domains, death effector domain, the caspase-recruitment domains, CIDE domains (cell-death inducing FDD45-like effectors), and inhibitors of apoptosis domains. The death domain is a relatively abundant protein module thought to allow for protein-protein complex assembly and propagate signaling, classically, in the NF-B and TNF family of cytokine receptors. The death domain protein interaction module has evolved combinatorially into larger proteins implicated in apoptosis that harbor caspase-like domains, IgG-like folds, leucine zippers, TNFR domains, and Rel-homology domains (24) . Mice having a mutation (named lpr) in the death domain of Fas exhibit a lupus-like lymphoproliferative autoimmune disorder (26) . The lpr mutation results in Fas death domain denaturation (27) , which explains why the lpr Fas domain is biochemically inactive.
The links between ERK activation, DAPK-1 signaling, and p53 function are only beginning to be unraveled. ERK is required to activate p53 gene expression and maintain p53 pathway activation status (44) . Further, DAPK-1 activates p53 in an oncogene signaling pathway by an undefined mechanism (7) . As such, ERK may co-ordinate p53 and DAPK-1 pathways to maintain p53 function as a tumor suppressor in response to oncogenic signaling. Two distinct ERK-dependent pathways control the specific activity of DAPK-1 (Fig. 7H) . The more classic ERK-dependent pro-survival pathway can be stimulated by ERK activation of RSK kinase, which in turn attenuates DAPK-1 pro-apoptotic activity (40) . Opposing this pathway (Fig. 7H) , direct interaction of ERK with the death domain of DAPK-1 can stimulate the pro-apoptotic activity of the ERK: DAPK-1 axis. In support of this model, a naturally occurring polymorphism in the death domain at codon 1347 reduces ERK binding and precludes ERK-triggered apoptosis (Fig. 7H) . Presumably, this would also reduce the specific activity of p53 when its function is being triggered by the DAPK-1 oncogenic signaling pathway.
Although inactivating mutations in the tumor suppressor p53 gene are one of the most common genetic changes in human cancers (29 -31) , a germ line mutation exists in the p53 gene at codon 72 within the transactivation domain-II that can alter apoptotic rates, cancer incidence, and anti-cancer drug responses (32, 33) . Interestingly, a relatively rare germ line mutation exists in the p53 gene at a MAPK kinase phosphorylation site near the p53 transactivation domain at Ser-47. This mutation can attenuate p53 phosphorylation by MAPK and reduce the induction of apoptosis (34) . The penetrance of the Pro 3 Ser codon 47 germ line mutation is apparently confined to African-American populations and the frequency of the S47 allele in this population is ϳ1-4% (35). This is considerably lower than the codon 72 mutation, which occurs at approximately similar ratios. Loss of heterozygosity at the p53 locus is relatively frequent in human cancers, and patients heterozygous for the codon 72 mutation preferentially lose the P72 allele in cancers (36) , suggesting a selective advantage in a tumor for retaining the pro-apoptotic R72 allele. Other germ line mutations in p53 regulators can also have an impact of p53 pathway function. p53 activity is normally kept low by an MDM2-dependent pathway, and germ line mutations in the MDM2 promoter that result in enhanced MDM2 protein production result in an attenuated p53 pathway as well as increase in the age of onset for particular types of cancer (37) .
It is possible that the death domain mutation in DAPK-1 might confer reduced apoptotic potential to the DAPK-1 pathway in vivo, and this might accelerate diseases where the p53-dependent or p53-independent apoptotic function of DAPK-1 maintains tissue integrity. Attenuated apoptosis in injured neurons, developing cancers, or in immune cell integrity might alter biological responses in vivo (41) . However, given our sequencing data showing the death domain mutation shows significant penetrance in one group of patients, the question is raised as to whether there have been selection pressures for maintaining the mutant allele in some populations during human evolution. Preliminary sequencing data in a distinct European population has surprisingly found no evidence of the Ser-1347 allele (data not shown). DAPK-1-mediated function is also involved in signaling pathways, including stress-induced autophagy (16) , TNF-mediated apoptosis (19) , ERK-dependent apoptosis (22) , and ischemic-mediated injury in neuronal cells (42) . Maintenance of the mutant Ser-1347 allele in the population might be linked to responses to infection and immunity related to fitness. Attenuated apoptosis conferred by the DAPK-1 death domain mutation might maintain T-cell responses to some infections and delay loss of cells involved in immunity or it might attenuate cell death involved in neuronal development, injury, or repair thus altering tissue integrity. Determining where DAPK-1 functions in normal and diseased conditions in vivo, and the signaling pathways that activate the protein under these conditions, will facilitate understanding of the effects of the DAPK-1 death domain mutation on tissue physiology.
